- Vincerx Pharma press release (NASDAQ:VINC): Q4 GAAP EPS of -$0.23 beats by $0.06.
- Vincerx had $12.8 million in cash and cash equivalents as of December 31, 2023, as compared to $52.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
- Based on its current business plans and assumptions, Vincerx believes its available capital will be sufficient to meet its operating requirements into early third quarter of 2024.
More on Vincerx Pharma
feed from seekingalpha.com